The study will test two treatments: platelet-rich plasma (PRP) injections, which use concentrated platelets from the patient’s own blood, compared to injections containing betamethasone (a steroid) and ropivacaine (a pain medication). Both groups of patients will also follow a personalized exercise program. The main goal is to determine if PRP injections combined with exercise are more effective at reducing shoulder pain and improving function than steroid injections with exercise.

During the study, patients will receive two injections of either PRP or the combination of betamethasone and ropivacaine. The treatment period lasts up to 15 days, and patients will be monitored for changes in their shoulder function and pain levels over six months. The effectiveness of the treatment will be measured using a special scoring system that evaluates shoulder function and pain.

The purpose of the study is to evaluate which treatment is more effective in improving shoulder functionality and reducing pain in patients with chronic shoulder pain. Participants in the study will be randomly assigned to receive either the corticosteroid injection or the pulsed radiofrequency treatment. The study is designed to be double-blind, meaning neither the participants nor the researchers will know which treatment each participant is receiving, to ensure unbiased results.

Throughout the study, participants will be assessed using various methods, including the Shoulder Pain and Disability Index (SPADI), which is a questionnaire that measures pain and disability related to shoulder issues. Other assessments will include scales for pain measurement, range of motion tests, and evaluations of overall quality of life. The study will help determine the most effective approach for managing chronic shoulder pain, potentially leading to better treatment options for those affected by this condition.

The purpose of the study is to see how well the PET scan can predict the development of rheumatoid arthritis in people with ACPA positive arthralgia. Participants will receive the PET scan and be monitored over a period of one year to see if they develop clinical arthritis, which means arthritis that can be diagnosed by a doctor. The study aims to determine how accurately the PET scan can identify those who are likely to develop arthritis.

During the study, participants will undergo a PET scan using the [18F]Fluor-PEG-Folate solution, which is administered through an injection into a vein. The study will track the participants’ health over the course of a year to observe any changes in their condition. The results will help researchers understand the relationship between PET scan results and the likelihood of developing rheumatoid arthritis, potentially leading to earlier and more accurate identification of individuals at risk.

Participants in the study will receive either the new medication ODM-111, a commonly used pain reliever called Paracetamol (known as Para-Tabs 500 mg), or a placebo. The study will last for a period of six weeks, during which participants will take the medication orally in the form of tablets. The goal is to see if ODM-111 can effectively reduce knee pain compared to the other treatments.

Throughout the study, participants will be monitored to assess any changes in their pain levels and to ensure their safety. The primary focus is on the change in pain from the beginning of the study to the end of the six-week period, using a specific pain measurement scale. This research is important for finding new ways to help people manage chronic knee pain caused by osteoarthritis.